Randomised, open-label, phase II trial of paclitaxel, gemcitabine and cisplatin versus gemcitabine and cisplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium.

@article{Lorusso2005RandomisedOP,
  title={Randomised, open-label, phase II trial of paclitaxel, gemcitabine and cisplatin versus gemcitabine and cisplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium.},
  author={Vito Lorusso and Enrico Crucitta and Nicola Silvestris and Gerardo Rosati and Luigi Manzione and Mario De Lena and Sergio Palmeri and Vittorio Gebbia and Sergio Mancarella and Alberto F. Sobrero and Giuseppe Pezzella and Pasquale Comella and Andrea Mangiameli and Domenico Muci},
  journal={Oncology reports},
  year={2005},
  volume={13 2},
  pages={283-7}
}
The purpose of the study was to evaluate the antitumor activity and the safety of paclitaxel combined with gemcitabine and cisplatin in patients affected by advanced transitional cell carcinoma of the urothelium (TCC). Eighty-five patients affected by advanced TCC and measurable disease were randomized to receive either paclitaxel at dosage of 70 mg/m2… CONTINUE READING